Phase 4 N=147 InSite for Over Active Bladder
Urinary Incontinence, Urgency-frequency · Overactive Bladder
Primary: Randomized Cohort: OAB Therapeutic Response — 61; 42 percentage of participants with response — p=0.016
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=177 Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine Surgery
Scoliosis
Primary: Total Blood Loss Over Course of Stay (Intraoperative and Postoperatively Until Discharge) — 1775; 2116; 1531 ml
Phase 4 N=196 The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery
Blood Loss
Primary: Change in Hemoglobin on Day 0 Compared to Preoperatively — -1.277; -1.241 g/dL
Phase 4 N=37 Effects of Ranolazine and Exercise on Daily Physical Activity Trial
Chronic Stable Angina
Primary: Change in Peak Oxygen Consumption (VO2 Max) — 0.03; 0.38; 0.9; 2.1 ml/kg/min — p=>0.05
Phase 4 N=17 Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils
Allergic Asthma
Primary: Changes in the Peripheral Blood Basophil Response to Crosslinking Anti-IgE Ab — 7.8 Fold change in basophil Syk expression
Phase 4 N=5 Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation
Kidney Failure, Chronic
Primary: C0 (ng/mL) — 1.45; 6.2; 1.25; 6.5 ng/mL
Phase 4 N=69 Varenicline Adjunctive Treatment in Schizophrenia
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Hamilton Depression Rating Scale (Ham-D) — 22.9; 20.6; 19.4; 18.6 units on a scale
Phase 4 N=54 The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine
Headache
Primary: Headache Following Intervention — 63.5; 43.5 mm
Phase 4 N=806 A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)
Asthma
Primary: Total Number of Asthma Exacerbations During Months 1-12 — 0.46; 0.81; 0.78 asthma exacerbations
Phase 4 N=291 Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery
Hypotension on Induction
Primary: Number of Participants With Interoperative Hypotension — 76; 95 Participants — p=0.03
Phase 4 N=56 Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia
Diabetes · Schizophrenia · Insulin Resistance
Primary: Change From Baseline in Serum Triglycerides at 3 Months ( 3 Months-baseline) US Sample — -49.65; 30.99 mg/dL
Phase 4 N=44 Vitamin D and Coronary Calcification Study
Chronic Kidney Disease · Vitamin D Deficiency · Coronary Calcification
Primary: Coronary Artery (CAC) Score Progression — 74.38; 106.32 Agatston units
Phase 4 N=70 Improvement of Pain Following Robotic Sacrocolpopexy and Rectocele Repair for Pelvic Organ Prolapse
Pelvic Organ Prolapse
Primary: Visual Analog Scales (VAS) for Pain at 18 Hours Postoperatively — 15.0; 20.5 mm — p=0.52
Phase 4 N=52 Assess the Effect of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognition in Healthy Volunteers
Healthy
Primary: Auditory Arousal Threshold (AAT) at T-max — 85.2; 78.0; 103.2; 84.7 Decibels (dB)
Phase 4 N=130 Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes · Coronary Heart Disease
Primary: Change in E to A Ratio — 1.04; 1.25 Ratio — p=<0.01